Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand

被引:55
|
作者
Plummer, MS
Holland, DR
Shahripour, A
Lunney, EA
Fergus, JH
Marks, JS
McConnell, P
Mueller, WT
Sawyer, TK
机构
[1] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT BIOCHEM, ANN ARBOR, MI 48105 USA
[2] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT BIOTECHNOL, ANN ARBOR, MI 48105 USA
关键词
D O I
10.1021/jm970402q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The specific association of an SH2 domain with a phosphotyrosine (pTyr)-containing sequence of another protein precipitates a cascade of intracellular molecular interactions (signals) which effect a wide range of intracellular processes. The nonreceptor tyrosine kinase Src, which has been associated with breast cancer and osteoporosis, contains an SH2 domain. Inhibition of Src SH2-phosphoprotein interactions by small. molecules will aid biological proof-of-concept studies which may lead to the development of novel therapeutic agents. Structure-based design efforts have focused on reducing the size and charge of Src SH2 ligands while increasing their ability to penetrate cells and reach the intracellular Src SH2 domain target. In this report we describe the synthesis, binding affinity, and Src SH2 cocrystal structure of a small, novel, nonpeptide, urea-containing SH2 domain ligand.
引用
收藏
页码:3719 / 3725
页数:7
相关论文
共 50 条
  • [21] Inhibition of bone resorption by src SH2 domain antagonists
    Dunnington, D
    Votta, B
    Hand, A
    Appelbaum, E
    Jones, C
    Prichett, W
    Holt, D
    Yamashita, D
    Gowen, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : T395 - T395
  • [22] Solid-phase binding assays of peptides using EGFP-Src SH2 domain fusion protein and biotinylated Src SH2 domain
    Ye, GF
    Ayrapetov, M
    Nam, NH
    Sun, GQ
    Parang, K
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (22) : 4994 - 4997
  • [23] Evolution of Src Homology 2 (SH2) Domain to Recognize Sulfotyrosine
    Ju, Tong
    Niu, Wei
    Guo, Jiantao
    ACS CHEMICAL BIOLOGY, 2016, 11 (09) : 2551 - 2557
  • [24] Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain
    Metcalf, CA
    Eyermann, CJ
    Bohacek, RS
    Haraldson, CA
    Varkhedkar, VM
    Lynch, BA
    Bartlett, C
    Violette, SM
    Sawyer, TK
    JOURNAL OF COMBINATORIAL CHEMISTRY, 2000, 2 (04): : 305 - 313
  • [25] Structure-based design of novel, dipeptide ligands targeting the pp60(Src) SH2 domain
    Shahripour, A
    Para, KS
    Plummer, MS
    Lunney, EA
    Holland, DR
    Rubin, JR
    Humblet, C
    Fergus, JH
    Marks, JS
    Saltiel, AR
    Sawyer, TK
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (09) : 1107 - 1112
  • [26] Design and synthesis of novel phsophoramidate prodrugs as SH2 domain inhibitors
    Huang, Rong
    Borch, Richard F.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2739 - U2739
  • [27] Inhibitors of the Src SH2 domain and Src tyrosine kinase as potential anticancer drugs
    Tranter, D
    DRUG DISCOVERY TODAY, 2001, 6 (04) : 215 - 216
  • [28] SH2 DOMAIN-STRUCTURE AND FUNCTION
    SCHAFFHAUSEN, B
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1995, 1242 (01): : 61 - 75
  • [29] Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain
    Stover, DR
    Furet, P
    Lydon, NB
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) : 12481 - 12487
  • [30] Synthesis of the Src SH2 domain and its application in bioassays for mirror-image screening
    Shu, Keitou
    Noguchi, Taro
    Honda, Kaori
    Kondoh, Yasumitsu
    Osada, Hiroyuki
    Ohno, Hiroaki
    Fujii, Nobutaka
    Oishi, Shinya
    RSC ADVANCES, 2017, 7 (61): : 38725 - 38732